dcsimg Aranesp® (darbepoetin alfa) – Dose Combinations Tool
› Email› Print

Aranesp® single-dose strengths can be combined
to address different patient needs1

Simply select one of the following doses to see which single-dose strengths may be combined to individualize anemia management.

Aranesp® single-dose strengths

Important Safety Information

  • In controlled clinical trials, ESAs increased the risk of death in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures.
  • Control hypertension prior to initiating and during treatment with Aranesp®.
  • Aranesp® increases the risk of seizures in patients with CKD. Monitor patients closely for new-onset seizures, premonitory symptoms, or change in seizure frequency.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
ESA = erythropoiesis-stimulating agent; QW = once weekly; Q2W = once every 2 weeks; Q4W = once every 4 weeks.
Reference: 1. Aranesp® (darbepoetin alfa) prescribing information, Amgen.

Biotechnology by Amgen®